Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label Phase III Study to Evaluate the Safety and Efficacy of ISU302 (Imiglucerase for Injection) in Patients With Type 1 Gaucher Disease

NCT02770625 is registered in ClinicalTrials.gov with ISU Abxis Co., Ltd. as lead sponsor.

NCT NCT02770625
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02770625 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label Phase III Study to Evaluate the Safety and Efficacy of ISU302 (Imiglucerase for Injection) in Patients With Type 1 Gaucher Disease
Lead sponsor
ISU Abxis Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2011
Completion date
August 31, 2014
Enrollment
8 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

gaucher disease, type 1